Effectiveness of agomelatine in usual clinical practice in major depressive disorders (MDD) outpatients

被引:0
作者
Lupo, C. [1 ]
Corral, R. [2 ]
Galeno, R. [3 ]
Marquez, M. [4 ]
机构
[1] CIAP Ctr Invest & Asistencia Psiquiatria Invest C, Rosario, Santa Fe, Argentina
[2] Hosp Jose T Borda, Fac Med, Buenos Aires, DF, Argentina
[3] Inst Neurociencias Invest Clin, Mendoza, Argentina
[4] ADINEU Asistencia Docencia & Invest Neurociencias, Buenos Aires, DF, Argentina
关键词
D O I
10.1016/S0924-977X(11)70643-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
引用
收藏
页码:S399 / S400
页数:2
相关论文
共 3 条
[1]   Placebo-controlled trial of agomelatine in the treatment of major depressive disorder [J].
Kennedy, SH ;
Emsley, R .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 (02) :93-100
[2]   Agomelatine in the Treatment of Major Depressive Disorder Potential for Clinical Effectiveness [J].
Kennedy, Sidney H. ;
Rizvi, Sakina J. .
CNS DRUGS, 2010, 24 (06) :479-499
[3]   Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder [J].
Olie, Jean Pierre ;
Kasper, Siegfried .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2007, 10 (05) :661-673